158 related articles for article (PubMed ID: 11961573)
41. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma.
Sun Y; Mi W; Cai J; Ying W; Liu F; Lu H; Qiao Y; Jia W; Bi X; Lu N; Liu S; Qian X; Zhao X
J Proteome Res; 2008 Sep; 7(9):3847-59. PubMed ID: 18646787
[TBL] [Abstract][Full Text] [Related]
42. Hepatoma, erythrocytosis and increased serum erythropoietin developing in long-standing hemochromatosis.
Scott D; Theologides A
Am J Gastroenterol; 1974 Mar; 61(3):206-11. PubMed ID: 4363553
[No Abstract] [Full Text] [Related]
43. Management of spontaneous bleeding due to hepatocellular carcinoma.
Recordare A; Bonariol L; Caratozzolo E; Callegari F; Bruno G; Di Paola F; Bassi N
Minerva Chir; 2002 Jun; 57(3):347-56. PubMed ID: 12029230
[TBL] [Abstract][Full Text] [Related]
44. Hemochromatosis, hepatoma, erythrocytosis, and erythropoietin.
Lizzi FA; Tartaglia AP; Adamson JW
N Y State J Med; 1973 May; 73(9):1098-100. PubMed ID: 4348807
[No Abstract] [Full Text] [Related]
45. [A Case of Hepatocellular Carcinoma with Erythrocytosis].
Mitsuhashi N; Sai G; Shimizu Y; Sakai N; Suzuki D; Kuboki S; Furukawa K; Ohtsuka M
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1771-1773. PubMed ID: 36732994
[TBL] [Abstract][Full Text] [Related]
46. The triad of hemochromatosis, hepatoma and erythrocytosis.
Raphael B; Cooperberg AA; Niloff P
Cancer; 1979 Feb; 43(2):690-4. PubMed ID: 217527
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
48. Hepatocellular carcinoma occurring in a young Crohn's disease patient.
Murakami A; Tanaka Y; Ueda M; Nagano Y; Kunisaki R; Morimoto M; Enaka M; Tanabe M; Kawachi K; Sasaki T; Nozawa A
Pathol Int; 2009 Jul; 59(7):492-6. PubMed ID: 19563414
[TBL] [Abstract][Full Text] [Related]
49. Intrahepatic cholangiocarcinoma detected by elevated levels of alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma in a patient with Budd-Chiari syndrome.
Yamamoto M; Otsubo T; Ariizumi S; Nakano M; Takasaki K
Int Surg; 2005; 90(2):81-4. PubMed ID: 16119710
[TBL] [Abstract][Full Text] [Related]
50. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.
Murugavel KG; Mathews S; Jayanthi V; Shankar EM; Hari R; Surendran R; Vengatesan A; Raghuram K; Rajasambandam P; Murali A; Srinivas U; Palaniswamy KR; Pugazhendhi T; Thyagarajan SP
Int J Infect Dis; 2008 Nov; 12(6):e71-6. PubMed ID: 18658001
[TBL] [Abstract][Full Text] [Related]
51. [Polyglobulia as a manifestation of a primary of the liver].
Cornet A; Barbier JP; Benisty H; Carnot F; Fraitag B
Ann Med Interne (Paris); 1978 Apr; 129(4):279-81. PubMed ID: 208447
[No Abstract] [Full Text] [Related]
52. [Polycythemia in liver diseases].
Desaint B; Conrad M; Florent C; Najman A; Levy VG
Ann Gastroenterol Hepatol (Paris); 1986 Dec; 22(7):399-404. PubMed ID: 3028242
[No Abstract] [Full Text] [Related]
53. Clinico-cytopathological spectrum of hepatocellular carcinoma, its correlation with serum alpha-fetoprotein level, and hepatitis B and C viral markers.
Radhika NS; Duseja A; Rajwanshi A; Gupta SK; Sehgal S; Suri S; Chawla Y
Trop Gastroenterol; 2004; 25(3):116-20. PubMed ID: 15682657
[TBL] [Abstract][Full Text] [Related]
54. The clinical manifestations and natural history of hepatocellular carcinoma.
Kassianides C; Kew MC
Gastroenterol Clin North Am; 1987 Dec; 16(4):553-62. PubMed ID: 2831150
[TBL] [Abstract][Full Text] [Related]
55. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
56. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis.
Cucchetti A; Vivarelli M; Piscaglia F; Nardo B; Montalti R; Grazi GL; Ravaioli M; La Barba G; Cavallari A; Bolondi L; Pinna AD
J Hepatol; 2005 Aug; 43(2):310-6. PubMed ID: 15970351
[TBL] [Abstract][Full Text] [Related]
57. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.
Xu J; Shi J; Wang YP; Lin Y; Chen YX; Lu J; Zeng X; Xie WF
Med Sci Monit; 2009 Jun; 15(6):CR274-9. PubMed ID: 19478697
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
[TBL] [Abstract][Full Text] [Related]
59. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India.
Kumar M; Kumar R; Hissar SS; Saraswat MK; Sharma BC; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2007 Jul; 22(7):1104-11. PubMed ID: 17559381
[TBL] [Abstract][Full Text] [Related]
60. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
